Editorial: Mechanisms of Inflammation and Fibrosis Interplays in the Digestive Diseases

Masamune, Atsushi; Hamada, Shin

doi:10.3389/fphys.2022.906742

Cited by 2 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This indicated that ASDURF may be a regulator of TGF-β1/Smad3 and NF-κB signaling pathways, and TGF-β1/Smad3 and NF-κB are important pathways in hepatic fibrosis. [3][4][5] This further supports the hypothesis that ASDURF is involved in managing hepatic fibrosis. The dual-luciferase test revealed that ASDURF enhanced ASNSD1 promoter activity, and Co-IP demonstrated that ASDURF could attach to ASNSD1 (Fig.…”

Section: Discussionsupporting

confidence: 78%

“…P‐smad3 and p‐p65 were downregulated after ASDURF interference in LX‐2 cell lines. This indicated that ASDURF may be a regulator of TGF‐β1/Smad3 and NF‐κB signaling pathways, and TGF‐β1/Smad3 and NF‐κB are important pathways in hepatic fibrosis 3–5 . This further supports the hypothesis that ASDURF is involved in managing hepatic fibrosis.…”

Section: Discussionsupporting

confidence: 67%

“…2,3 Additionally, NF-κB controls hepatic fibrogenesis. 4,5 Furthermore, the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling pathway is linked to HSC activation, proliferation, and extracellular matrix production according to a number of studies. 6,7 This was used as the backdrop to explore the function of the PAQosome in hepatic fibrosis.…”

Section: Introductionmentioning

confidence: 99%

“…The most traditional method for activating HSCs is through the transforming growth factor‐β1 (TGFβ1)/ Sekelsky mothers against decapentaplegic homologue 3 (Smad3) signaling pathway 2,3 . Additionally, NF‐κB controls hepatic fibrogenesis 4,5 . Furthermore, the phosphatidylinositol 3‐kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling pathway is linked to HSC activation, proliferation, and extracellular matrix production according to a number of studies 6,7 .…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Potential of PAQosome as a therapeutic target for hepatic fibrosis

Shi,

Feng,

Yang

et al. 2023

J of Gastro and Hepatol

View full text Add to dashboard Cite

Background and AimThe condition of hepatic fibrosis is hazardous. Therefore, it is vital that we investigate the mechanism of hepatic fibrosis to provide new targets for treatment.MethodsPreliminary screening and research was carried out based on our prior results and our speculated role of the particle with quaternary structure arrangement (PAQosome) in hepatic fibrosis. The experiments were conducted using LX‐2 or HepG2 cell lines by western blotting, quantitative real‐time polymerase chain reaction, luciferase assays, and co‐immunoprecipitation and were further validated in the Gene Expression Omnibus (GEO) database.ResultsWe screened and proved that several subunits of the PAQosome regulate the development of liver fibrosis, including the asparagine synthetase domain‐containing 1 upstream open reading frame (ASDURF), prefoldin subunit 4 (PFDN4), prefoldin subunit 5 (PFDN5), unconventional prefoldin RNA polymerase II subunit 5 interactor (URI1), and ubiquitously expressed prefoldin‐like chaperone (UXT). ASDURF promotes hepatic fibrosis through the transforming growth factor‐β1 (TGFβ1)/Sekelsky mothers against decapentaplegic homologue 3 (Smad3) and NF‐κB signaling pathways. ASDURF regulates the expression of asparagine synthetase domain‐containing 1 (ASNSD1). PFDN4, PFDN5, URI1, and UXT regulate cell proliferation through the PI3K/AKT pathway, and thus regulate liver fibrosis. A hepatic fibrosis score ≥ F2 was selected as the diagnostic criteria for hepatic fibrosis in the GSE96971 database. The area under the receiver operating characteristic curve of PFDN4, PFDN5, UXT, and ASNSD1 were 0.862 (confidence interval [CI]: 0.6588–1.000), 0.538 (CI: 0.224–0.853), 0.708 (CI: 0.449–0.966), and 0.831 (CI: 0.638–1.000), respectively.ConclusionsThese findings demonstrate that the PAQosome is a brand new target for hepatic fibrosis therapy.

show abstract

Section: Discussionsupporting

confidence: 78%

Section: Discussionsupporting

confidence: 67%